Colin Campbell, DO
Internal Medicine · West Berlin, NJNPI 1477518132
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 65 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations.
Across 65 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$176
- Pfizer$140
- AbbVie$109
- Kowa Pharmaceuticals America, Inc.$73
- Amgen$70
- Lilly USA, LLC$64
- plus $349 from 14 others
Across 12 payments — averaging $75,885 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hikma Pharmaceuticals USA$784K
- Astrazeneca UK Limited$127K
What the payments were for
- Food & beverage$983100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 12 | $176 |
| Pfizer | 9 | $140 |
| AbbVie | 7 | $109 |
| Kowa Pharmaceuticals America, Inc. | 5 | $73 |
| Amgen(2 entities) | 5 | $70 |
| Lilly USA, LLC | 4 | $64 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| GSK | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $39 |
| Exact Sciences | 2 | $36 |
| Merck | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Johnson & Johnson | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
| AstraZeneca | 1 | $11 |
| My01 Inc. | 1 | $11 |
How this compares
$983 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $87,926 |
| JardianceEmpagliflozin | 49 | $59,880 |
| MounjaroTirzepatide | 27 | $29,161 |
| XareltoRivaroxaban | 30 | $27,593 |
| JanuviaSitagliptin Phosphate | 13 | $18,645 |
| TradjentaLinagliptin | 17 | $10,177 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $8,843 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,407 |
| BelsomraSuvorexant | 11 | $4,759 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $4,511 |
| Atorvastatin Calcium | 317 | $3,627 |
| Varenicline Tartrate | 13 | $3,574 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 102 | $3,270 |
| Gabapentin | 208 | $3,167 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $3,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $140 | $87,92669 claims |
| Boehringer IngelheimJardiance, Tradjenta | $176 | $70,05766 claims |
| Lilly USA, LLCMounjaro | $64 | $29,16127 claims |
| Johnson & JohnsonXarelto | $18 | $27,59330 claims |
| MerckJanuvia, Belsomra | $33 | $23,40324 claims |
| GSKBreo Ellipta | $46 | $8,84323 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $27 | $6,40713 claims |
| AbbVieSynthroid | $109 | $1,26417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in West Berlin
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.